Clinical trials in Heilbronn – page 80

987 clinical trials in Heilbronn, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Heilbronn at a glance

987

clinical trials

Research sites1

Quick filters

987 trials in Heilbronn

Open in trial search

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Aflibercept
Sponsor:Bayer AG

Contact Research Centre

Squamous cell carcinoma of head and neck+1

Not recruiting

Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Io Biotech ApS

Contact Research Centre

Diffuse large B-cell lymphoma+1

Not recruiting

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo

Study on the Effectiveness and Safety of Glofitamab with Drug Combination for Untreated Large B-Cell Lymphoma Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Renal cell carcinoma stage IV+1

Not recruiting

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo

Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug

Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo

Study Comparing Patritumab Deruxtecan and Platinum-based Chemotherapy for Patients with Advanced EGFR-mutated Non-small Cell Lung Cancer After EGFR Therapy Failure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study on Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

Registered drugNo placebo

Study on Atezolizumab and Bevacizumab for Patients with Unresectable Liver Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Klinikum der Universitaet Muenchen AöR

Contact Research Centre

Diabetes mellitus

Not recruiting

A Study of Long-Term Safety of Teplizumab in Children and Adolescents with Recently Diagnosed Type 1 Diabetes

InvestigationalNo placebo

A Study of Long-Term Safety of Teplizumab in Children and Adolescents with Recently Diagnosed Type 1 Diabetes

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Teplizumab
Sponsor:Provention Bio Inc.

Contact Research Centre

Anal squamous cell carcinoma+5

Not recruiting

Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

Registered drugNo placebo

Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Oncolytics Biotech Inc.

Contact Research Centre

Pancreatic neuroendocrine tumour

Not recruiting

Study of Ramucirumab and Dacarbazine for Patients with Progressive Metastatic Pancreatic Neuroendocrine Tumors

Registered drugNo placebo

Study of Ramucirumab and Dacarbazine for Patients with Progressive Metastatic Pancreatic Neuroendocrine Tumors

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ramucirumab
Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Contact Research Centre

Gastrooesophageal cancer+1

Not recruiting

Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer

Registered drugNo placebo

Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Cholangitis sclerosing

Not recruiting

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Investigational

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Norucholic Acid
Sponsor:Dr. Falk Pharma GmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Heilbronn

What the registry says about research in the country

01 Blood Cancers

Innovative trials focusing on Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia, testing novel drug combinations to improve patient outcomes. Research includes evaluating treatments for both adult and pediatric patients with various forms of leukemia.

Novel drug combinations for AML treatment
Targeted therapies for specific genetic mutations
Pediatric leukemia protocols

Studies aim to enhance survival rates and develop more effective treatment strategies for blood cancer patients.

02 Breast Cancer Research

Comprehensive studies addressing different types of breast cancer, particularly focusing on triple-negative breast cancer and HER2-positive disease. Research includes both early-stage and metastatic disease treatments.

Advanced therapeutic approaches for TNBC
Adjuvant therapy optimization
Personalized treatment strategies

Trials evaluate novel drug combinations and targeted therapies to improve patient outcomes.

03 Gastrointestinal Oncology

Research focusing on various digestive system cancers, including gastric cancer, colorectal cancer, and pancreatic cancer. Studies evaluate both early-stage and advanced disease treatments.

Advanced gastric cancer therapies
Preoperative treatment strategies
Novel combination approaches

Investigations aim to improve surgical outcomes and treatment effectiveness for GI cancers.

Back to Germany All countries